Scottsdale 1/31/2014 4:00:00 AM
News / Stocks

QualityStocks News - Hanover Portfolio Acquisitions (HVPA) Changes Name to Endonovo Therapeutics

QualityStocks would like to highlight Endonovo Therapeutics (OTCQB: HVPA), a biotechnology company developing non-invasive electromagnetic therapies for inflammatory, autoimmune, and degenerative diseases. The company's core technologies, Time-Varying Electromagnetic Fields (TVEMF), were originally developed at NASA to combat muscle and bone mass loss due to microgravity environments.

In the company’s news,

Hanover Portfolio Acquisitions has announced that, effective immediately, it will now operate under the name Endonovo Therapeutics.

As part of this change, the company’s website, www.hanoverpai.com, has officially been changed to www.endonovo.com. The company’s email addresses will soon migrate to an @endonovo.com suffix.

The adoption of the name Endonovo Therapeutics coincides with the company’s development of noninvasive, time-varying electromagnetic field (TVEMF) therapies for inflammatory, autoimmune, and degenerative diseases, including diabetes, liver disease, and cardiovascular disease. Endonovo Therapeutics’ technology has the capability to mobilize and expand stem cells 80-fold to therapeutic levels, as well as up-regulate hundreds of components involved in the healing/regeneration process without using drugs.

The company began developing this technology in the 1980s at NASA in order to create therapies for diseases and injuries that could be experienced by astronauts during long-term manned missions in outer space. Endonovo Therapeutics is now seeking to apply this knowledge, gained over 25 years, regarding the effects of microgravity and the earth’s magnetic field on specific cells to treat diseases for earthbound patients.

“The change from Hanover Portfolio Acquisitions to Endonovo Therapeutics comes at a defining point in our company’s history,” said company CEO Alan Collier. “We have independent third-party studies that confirm the safety of our technology. The next step is to conduct clinical trials to prove the efficacy of our technology in treating several diseases.”

About QualityStocks

QualityStocks, based in Scottsdale, Arizona, is a free service that collects data from hundreds of Small-Cap and Micro-Cap online Investment Newsletters into one Daily Newsletter Report. QualityStocks is dedicated to assisting emerging public companies with their investor communication efforts and connecting subscribers with companies that have huge potential to succeed in the short and long-term future.

To sign up for The QualityStocks Daily Newsletter, please visit www.QualityStocks.net  

To connect with QualityStocks via Facebook, please visit http://Facebook.com/QualityStocksPage

To connect with QualityStocks via Twitter, please visit http://Twitter.com/QualityStocks

Please read FULL disclaimer on the QualityStocks website: http://Disclaimer.QualityStocks.net   

Forward-Looking Statement:

This release may contain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All forward-looking statements are inherently uncertain as they are based on current expectations and assumptions concerning future events or future performance of the company. Readers are cautioned not to place undue reliance on these forward-looking statements, which are only predictions and speak only as of the date hereof. Risks and uncertainties applicable to the company and its business could cause the company's actual results to differ materially from those indicated in any forward-looking statements.